Sinclair Pharma (XPAR:SPH) EV-to-EBITDA : -148.20 (As of May. 23, 2024)

View and export this data going back to . Start your Free Trial

What is Sinclair Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Sinclair Pharma's enterprise value is €134.12 Mil. Sinclair Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2018 was €-0.91 Mil. Therefore, Sinclair Pharma's EV-to-EBITDA for today is -148.20.

The historical rank and industry rank for Sinclair Pharma's EV-to-EBITDA or its related term are showing as below:

XPAR:SPH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -63266.7 Med: -12.8 Max: 54.7
Current: -234.4

During the past 13 years, the highest EV-to-EBITDA of Sinclair Pharma was 54.70. The lowest was -63266.70. And the median was -12.80.

XPAR:SPH's EV-to-EBITDA is not ranked
in the Drug Manufacturers industry.
Industry Median: 14.56 vs XPAR:SPH: -234.40

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-23), Sinclair Pharma's stock price is €0.27. Sinclair Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2018 was €0.000. Therefore, Sinclair Pharma's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.

Sinclair Pharma EV-to-EBITDA Historical Data

The historical data trend for Sinclair Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sinclair Pharma EV-to-EBITDA Chart

Sinclair Pharma Annual Data

Trend

Jun07

Jun08

Jun09

Jun10

Jun11

Jun12

Jun13

Jun14

Jun15

Dec17

EV-to-EBITDA

Get a 7-Day Free Trial

-58,862.40

-11.41

32.91

-46.70

44.68

Sinclair Pharma Semi-Annual Data
	Jun08	Dec08	Jun09	Dec09	Jun10	Dec10	Jun11	Dec11	Jun12	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Jun17	Dec17	Jun18
EV-to-EBITDA	Get a 7-Day Free Trial															-	-	-	44.68	-

Competitive Comparison of Sinclair Pharma's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Sinclair Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sinclair Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sinclair Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sinclair Pharma's EV-to-EBITDA falls into.

Sinclair Pharma EV-to-EBITDA Calculation

Sinclair Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA	=	Enterprise Value (Today)	/	EBITDA (TTM)
	=	134.117	/	-0.905
	=	-148.20

Sinclair Pharma's current Enterprise Value is €134.12 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinclair Pharma's EBITDA for the trailing twelve months (TTM) ended in Jun. 2018 was €-0.91 Mil.

Sinclair Pharma (XPAR:SPH) EV-to-EBITDA Explanation

Sinclair Pharma's PE Ratio for today is calculated as:

PE Ratio	=	Share Price (Today)	/	Earnings per Share (Diluted) (TTM)
	=	0.27	/	0.000
	=	N/A

Sinclair Pharma's share price for today is €0.27.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinclair Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2018 was €0.000.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?

Sinclair Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sinclair Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Sinclair Pharma (XPAR:SPH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sinclair Pharma PLC (XPAR:SPH) » Definitions » EV-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.sinclairispharma.com

Sinclair Pharma PLC is a United Kingdom-based specialty pharmaceutical company focused on Dermatology, in particular, Aesthetics, Wound care, and Skin care. The group has a direct sales and marketing presence in the top five European markets and a rapidly growing International division concentrated on key emerging markets through long-term multi-product, multi-country, sales & marketing and distribution deals with key strategic partners. The Company's reportable operating segments are International Operations, France, Italy, Germany, UK, and Spain.